Graft-versus-host disease

The U.S. Food and Drug Administration ( FDA ) has approved Jakafi ( Ruxolitinib ) for the treatment of steroid-refractory...


The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...


A major clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital ( BWH ) has...


Stimulators of the soluble guanylate cyclase ( sGC ) have recently been shown to inhibit transforming growth factor-beta ( TGF-beta...


Acute graft-versus-host disease ( GVHD ) remains a barrier to more widespread application of allogeneic haemopoietic stem-cell transplantation. Vorinostat (...


In humans, mutations in the gene encoding for forkhead box P3 ( FOXP3 ), a critically important transcription factor for...


No plasma biomarkers are associated with the response of acute graft-versus-host disease ( GVHD ) to therapy after allogeneic hematopoietic...


No plasma biomarkers are associated with the response of acute graft-versus-host disease ( GVHD ) to therapy after allogeneic hematopoietic...


T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation ( HSCT ) is a suitable option for patients in need of an...


Gastrointestinal graft-versus-host disease is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to...


Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease ( GVHD ) after hematopoietic-cell transplantation....